EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ascendis Pharma AS's enterprise value is R$5,914 Mil.
Ascendis Pharma AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was R$2,304 Mil. Therefore, Ascendis Pharma AS's EV-to-Revenue for today is 2.57.
The historical rank and industry rank for Ascendis Pharma AS's EV-to-Revenue or its related term are showing as below:
BSP:A1SN34'
s EV-to-Revenue Range Over the Past 10 Years
Min: 15.4 Med: 200.69 Max: 6014.17
Current: 27.6
During the past 13 years, the highest EV-to-Revenue of Ascendis Pharma AS was 6014.17. The lowest was 15.40. And the median was 200.69.
BSP:A1SN34's EV-to-Revenue is ranked worse than 73.84% of 990
companies
in the Biotechnology industry
Industry Median: 6.895
vs BSP:A1SN34: 27.60
The historical data trend for Ascendis Pharma AS's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ascendis Pharma AS's EV-to-Revenue
For the Biotechnology subindustry, Ascendis Pharma AS's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's EV-to-Revenue falls into.
Ascendis Pharma AS's current Enterprise Value is R$5,914 Mil.
Ascendis Pharma AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2,304 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (BSP:A1SN34) EV-to-Revenue Explanation
Ascendis Pharma AS's share price for today is R$64.60.
Ascendis Pharma AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$38.87.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ascendis Pharma AS's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:A1SN34 has been successfully added to your 